1
|
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, der Houven van Oordt CWMV. Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. Eur J Nucl Med Mol Imaging 2020; 47:2481. [PMID: 32535653 DOI: 10.1007/s00259-020-04908-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Missing Electronic Supplementary Materials.
Collapse
Affiliation(s)
- E J van Helden
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - S G Elias
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - S L Gerritse
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - S C van Es
- Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - E Boon
- Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
| | - M C Huisman
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - N C T van Grieken
- Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - H Dekker
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - G A M S van Dongen
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - D J Vugts
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - R Boellaard
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - C M L van Herpen
- Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
| | - E G E de Vries
- Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - W J G Oyen
- Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.,The Institute of Cancer Research and The Royal Marsden Hospital, London, UK
| | - A H Brouwers
- Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - H M W Verheul
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - O S Hoekstra
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands
| | - C W Menke-van der Houven van Oordt
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands. .,Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. .,Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. .,Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands. .,Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands. .,Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands. .,Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands. .,The Institute of Cancer Research and The Royal Marsden Hospital, London, UK. .,Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
| |
Collapse
|
2
|
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW. [ 89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. Eur J Nucl Med Mol Imaging 2019; 47:849-859. [PMID: 31705176 PMCID: PMC7076055 DOI: 10.1007/s00259-019-04555-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Accepted: 09/24/2019] [Indexed: 10/29/2022]
Abstract
PURPOSE One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. PATIENTS AND METHODS PET/CT imaging of [89Zr]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m2 ≤ 2 h) cetuximab was performed at the start of treatment. Patients without visual tumor uptake underwent dose escalation and a subsequent [89Zr]Zr-cetuximab PET/CT. Treatment benefit was defined as stable disease or response on CT scan evaluation after 8 weeks. RESULTS Visual tumor uptake on [89Zr]Zr-cetuximab PET/CT was observed in 66% of 35 patients. There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29). However, in 67% of PET-negative patients, cetuximab dose escalation (750-1250 mg/m2) was applied, potentially influencing outcome in this group. None of the second [89Zr]Zr-cetuximab PET/CT was positive. Eighty percent of patients without visual tumor uptake had treatment benefit, making [89Zr]Zr-cetuximab PET/CT unsuitable as a predictive biomarker. Tumor SUVpeak did not correlate to changes in tumor size on CT (P = 0.23), treatment benefit, nor progression-free survival. Cetuximab pharmacokinetics were not related to treatment benefit. BRAF mutations, right-sidedness, and low sEGFR were correlated with intrinsic resistance to cetuximab. CONCLUSION Tumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients with RAS wild-type mCRC receiving cetuximab monotherapy. BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.
Collapse
Affiliation(s)
- E J van Helden
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - S G Elias
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - S L Gerritse
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - S C van Es
- Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - E Boon
- Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - M C Huisman
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - N C T van Grieken
- Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - H Dekker
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - G A M S van Dongen
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - D J Vugts
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - R Boellaard
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - C M L van Herpen
- Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - E G E de Vries
- Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - W J G Oyen
- Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
- The Institute of Cancer Research and The Royal Marsden Hospital, London, UK
| | - A H Brouwers
- Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - H M W Verheul
- Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | - O S Hoekstra
- Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
| | | |
Collapse
|